ESR1 and breast cancer: In breast cancer, although high EZH2 and low H3K27me3 correlate with poor prognosis of estrogen receptor-positive (ER+) breast cancers, the methyltransferase EZH2 is not required for mammary cancer development (Bae et al., 2015).